Dialysis removes apolipoprotein C-I, improving very low-density lipoprotein clearance

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Chronic kidney disease (CKD) is associated with dyslipidemia, characterized by increased levels of triglyceride-rich lipoproteins (TRLPs), including very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL), with no change or a reduction in low-density lipoprotein (LDL) and low high-density lipoprotein (HDL) levels. Serum triglycerides and IDL are risk factors for vascular disease in dialysis patients, whereas LDL is not. The principal cause of the increase in TRLPs is decreased removal, not increased synthesis. The clearance defect arises from a reduction in specific lipoprotein receptors, decreases in the activity of lipases, and increased levels of low-molecular weight apolipoproteins that inhibit the interaction between TRLPs and both the receptors and the lipases that catabolize them. VLDL from dialysis patients is structurally abnormal and is not metabolized at a normal rate by lipoprotein lipase (LPL).

Original languageEnglish (US)
Pages (from-to)779-781
Number of pages3
JournalKidney International
Volume72
Issue number7
DOIs
StatePublished - Oct 2007

Fingerprint

Apolipoprotein C-I
VLDL Lipoproteins
Dialysis
Triglycerides
LDL Lipoproteins
IDL Lipoproteins
Lipoprotein Receptors
Lipase
Lipoproteins
Lipoprotein Lipase
Apolipoproteins
HDL Lipoproteins
Dyslipidemias
Chronic Renal Insufficiency
Vascular Diseases
Molecular Weight
Serum

ASJC Scopus subject areas

  • Nephrology

Cite this

Dialysis removes apolipoprotein C-I, improving very low-density lipoprotein clearance. / Kaysen, George.

In: Kidney International, Vol. 72, No. 7, 10.2007, p. 779-781.

Research output: Contribution to journalArticle

@article{657a14851ecd488a9ca254432d625c6f,
title = "Dialysis removes apolipoprotein C-I, improving very low-density lipoprotein clearance",
abstract = "Chronic kidney disease (CKD) is associated with dyslipidemia, characterized by increased levels of triglyceride-rich lipoproteins (TRLPs), including very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL), with no change or a reduction in low-density lipoprotein (LDL) and low high-density lipoprotein (HDL) levels. Serum triglycerides and IDL are risk factors for vascular disease in dialysis patients, whereas LDL is not. The principal cause of the increase in TRLPs is decreased removal, not increased synthesis. The clearance defect arises from a reduction in specific lipoprotein receptors, decreases in the activity of lipases, and increased levels of low-molecular weight apolipoproteins that inhibit the interaction between TRLPs and both the receptors and the lipases that catabolize them. VLDL from dialysis patients is structurally abnormal and is not metabolized at a normal rate by lipoprotein lipase (LPL).",
author = "George Kaysen",
year = "2007",
month = "10",
doi = "10.1038/sj.ki.5002478",
language = "English (US)",
volume = "72",
pages = "779--781",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Dialysis removes apolipoprotein C-I, improving very low-density lipoprotein clearance

AU - Kaysen, George

PY - 2007/10

Y1 - 2007/10

N2 - Chronic kidney disease (CKD) is associated with dyslipidemia, characterized by increased levels of triglyceride-rich lipoproteins (TRLPs), including very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL), with no change or a reduction in low-density lipoprotein (LDL) and low high-density lipoprotein (HDL) levels. Serum triglycerides and IDL are risk factors for vascular disease in dialysis patients, whereas LDL is not. The principal cause of the increase in TRLPs is decreased removal, not increased synthesis. The clearance defect arises from a reduction in specific lipoprotein receptors, decreases in the activity of lipases, and increased levels of low-molecular weight apolipoproteins that inhibit the interaction between TRLPs and both the receptors and the lipases that catabolize them. VLDL from dialysis patients is structurally abnormal and is not metabolized at a normal rate by lipoprotein lipase (LPL).

AB - Chronic kidney disease (CKD) is associated with dyslipidemia, characterized by increased levels of triglyceride-rich lipoproteins (TRLPs), including very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL), with no change or a reduction in low-density lipoprotein (LDL) and low high-density lipoprotein (HDL) levels. Serum triglycerides and IDL are risk factors for vascular disease in dialysis patients, whereas LDL is not. The principal cause of the increase in TRLPs is decreased removal, not increased synthesis. The clearance defect arises from a reduction in specific lipoprotein receptors, decreases in the activity of lipases, and increased levels of low-molecular weight apolipoproteins that inhibit the interaction between TRLPs and both the receptors and the lipases that catabolize them. VLDL from dialysis patients is structurally abnormal and is not metabolized at a normal rate by lipoprotein lipase (LPL).

UR - http://www.scopus.com/inward/record.url?scp=34648837114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34648837114&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5002478

DO - 10.1038/sj.ki.5002478

M3 - Article

C2 - 17882238

AN - SCOPUS:34648837114

VL - 72

SP - 779

EP - 781

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 7

ER -